Warberg Asset Management’s Decoy Therapeutics DCOY Stock Holding History

Warberg Asset Management’s Portfolio DCOY Stock Details DCOY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,333	Closed	-$18.2K	–	210
2025 Q4	$18.2K	Buy	+2,333	New	+$60.5K	﹤0.01%	162

Other funds holding DCOY

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Warberg Asset Management's DCOY Position: Q1 2026 in Review

Warberg Asset Management sold out of Decoy Therapeutics (DCOY) in Q1 2026, closing a stake of 2,333 shares — an estimated $18.2K sold.

Warberg Asset Management first reported a position in DCOY in Q4 2025 and held it in 1 quarter. The position peaked at $18.2K in Q4 2025. 4 funds tracked by Wall St. Rank hold DCOY as of Q1 2026.

Warberg Asset Management reported no remaining Decoy Therapeutics position as of Q1 2026 after selling out during the quarter.
Warberg Asset Management sold 2,333 Decoy Therapeutics shares in Q1 2026, an estimated $18.2K.
Warberg Asset Management first reported a position in Decoy Therapeutics in Q4 2025 and held it in 1 quarter.
Warberg Asset Management's Decoy Therapeutics position peaked at $18.2K in Q4 2025.
4 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q1 2026.

Based on Warberg Asset Management's 13F filing for Q1 2026, filed 7 May 2026.